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OBJECTIVES: Personalized medicine is characterized by an increasing number of
tests andpayer scrutiny over their value. Depending on the use of a test, health care
costs and outcomes may change in predictable ways. METHODS: We describe six
uses of tests, matching each with value hypotheses and a generic decision tree
framework thatmay be used to study test cost-effectiveness.Wemake distinctions
between screening (to identify those in a population likely to have or develop a
disease), diagnostic (to diagnose), predictive (to predict response to or toxicity from
a particular treatment, often referred to as a companion diagnostic), prognostic (to
identify patients at risk for a specific outcome, regardless of the choice of treat-
ment), surveillance (for patients with no sign of disease at completion of treatment
to identify those at risk of recurrence), andmonitoring (to detect response to treat-
ment or disease progression) tests. We specify how each test is expected to affect
health care costs and/or outcomes, followed by the nature and direction of the
effects.We also show the importance of properlymodeling the distinction between
these tests. For example, by identifying earlier or more accurately patients at
higher risk, a new screening test may lead to diagnosis at lower levels of disease
severity, resulting (from treatment) in improved life expectancy (LE) and/or quali-
ty-adjusted LE. Also, by identifying patients at lower risk, a new screening testmay
reduce costs associated with unnecessary future testing. Comparatively, we find
that salient elements of a general model structure for a new screening test include
screening compliance and distribution by severity at diagnosis, which are less
pertinent to other test uses. CONCLUSIONS: Testsmay be expected to affect health
care costs and outcomes in predictableways depending on the type of test; we offer
model structures that reflect these distinctions.
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TURNING THE IMPLAUSIBLE TO THE PLAUSIBLE: TOWARDS A BETTER
CONTROL OF OVER THE COUNTER DISPENSING OF ANTIBIOTICS IN EGYPT
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As a developing country, Egypt has long suffered negative outcomes from irrational
drug dispensing practices. This affected health economics adversely and increased
the burden of antibiotic resistance. With limited research data on this specific area
in Egypt, it becomes imperative to guide the researchers to potential adverse ef-
fects of over-the-counter dispensing on antibiotic resistance prevalence. This re-
search aims to define the flaws in antibiotic dispensing in Egypt and its impact on
the access to antibiotics. Spending on pharmaceuticals in Egypt constitutes 34% of
the total health care spending. TheMinistry of Health and Population has enforced
several laws prohibiting over-the-counter dispensing of drugs. However, there is
limited evidence on the effectiveness of those regulations on inappropriate dis-
pensing. Literature review revealed that only one report that dates back to 1998
addressed this area of inquiry. Analysis of 1174 dispensed products in 25 different
districted pharmacies in Alexandria showed that 60% of medications dispensed
were without a prescription or a pharmacist recommendation. Among those prod-
ucts, there were 98 different antibiotic products of which 42% were dispensed
without a prescription. Over all, Egypt suffers a high percentage of over-the-coun-
ter dispensing of drugswith little studies paying attention to this aspect in terms of
antibiotic resistance patterns. Despite enforced laws prohibiting over-the-counter
dispensing of drugs, further interventions are required. More strict laws must ap-
ply to pharmacists who do not complywith the official regulations of drug dispens-
ing. Further studies should inquire into non-optimal dispensing practices. Educa-
tional campaigns for patients to increase their level of awareness are crucial to
decrease wasteful drug spending and ensure approximate containment of newly
emerging antibiotic resistance in the near future.
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TRADE-OFF ANALYSIS: AN EXTENSION OF THRESHOLD PRICING ANALYSIS
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BACKGROUND: Investment decisions aremade on the basis of whether a new drug
is expected to meet certain criteria specified in a target product profile (TPP). Sim-
ilarly, such decisions assume a target price, which is used in calculations of return-
on-investment. Assuming a payer-cost-effectiveness threshold, threshold pricing
models are used to estimate themaximumvalue-based price assuming a new drug
achieves its TPP, and to estimate minimum value-based efficacy, safety, and toler-
ability required to support a target price. To assess the effects of uncertainty, one-
way and probabilistic sensitivity analyses may be tailored to apply to threshold
pricing models; however, to assess the risk to attaining a target price if a new drug
were to fail to achieve a particular criterion, it is essential to understand the rela-
tionships among the criteria listed in the TPP.METHODS:Wedescribe an extension
of threshold pricing analysis to include trade-off assessment. For example, a new
drug may be expected to reduce the risk of hospitalization, reduce hospital length
of stay, and reduce mortality, each by a certain amount, the combined achieve-
ment of which supports a particular value-based priced. Using trade-off analysis, it
is possible to estimate the improvement required in one attribute to offset the
failure of the new drug to achieve the expected effect in another attribute. In our
example, trade-off analysismay suggest that if the newdrugwere to fail to produce
an expected 5% mortality reduction, the new drug will need to quadruple the
reduction in hospital length of stay to achieve the same value based price. We
present tabular and graphical depictions of how multiple target attribute levels
may offset each other in a new drug’s ability to achieve a value-based price.
CONCLUSIONS: Trade-off analyses when applied to a threshold-pricingmodel can
make important contributions to value-based product development.
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OPERATIONALISING MULTIPLE CRITERIA DECISION ANALYSIS FOR HEALTH
TECHNOLOGY ASSESSMENT
Thokala P
University of Sheffield, Sheffield, UK
OBJECTIVES: To discuss the different methods of multi criteria decision analysis
(MCDA) that could be used in health technology assessment (HTA) and their rela-
tive merits. METHODS: The current practice of health technology appraisals is
based on the incremental cost-effectiveness ratio (ICER) i.e. the incremental cost
per quality adjusted life year (QALY) gained by recipients of treatment. Even though
other factors (e.g. severity, life saving, etc) are considered alongwith ICERs, there is
concern that its approach may fail to capture other important sources of value.
MCDA is aimed at supporting decision makers faced with evaluating alternatives
taking into account multiple, and often conflictive, criteria in an explicit manner.
This paper addresses a number of important questions to identify the most appro-
priate MCDAmethod that might be used to support decisionmaking. For example,
what criteria should be incorporated? Whose weights should be used and how to
elicit them? How to incorporate uncertainty into the MCDA process? How do we
consider the value of displaced technologies? What should the ‘basic’ cost-effec-
tiveness threshold be? How do we estimate it? This paper will discuss these ques-
tions, outline and assess methodological issues that would be raised by the use of
MCDA in health technology assessment (HTA). RESULTS: A potential MCDA ap-
proach for HTA is to calculate “weighted” QALYs from the QALY weights which
reflect the broader value of the product’s benefits and compare against the updated
“basic threshold” value. CONCLUSIONS: There are general practical issues that
might arise from using this MCDA approach in the HTA process and further re-
search needs to be performed to address the issues identified in order to ensure the
success of this MCDA technique in the appraisal process.
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SOCIAL VALUE SET FOR MEASURING HEALTH GAINS
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Regulatory authorities inmany countries require that societal preferences are used
when health (dis)benefits are reported in terms of quality-adjusted life-years
(QALYs). In the United Kingdom the NICE reference case, as set out in its published
technical guidance, cites EQ-5D as the requisite health-related quality of life
(HrQoL) system and Time Trade-Off (TTO) as the preferred method for eliciting
societal values. This stipulation is simple to assert, but virtually impossible to
justify and/or operationalise in practice. Nevertheless this has been the UK default
position for many years and has established a de facto national “norm”. These
issues, however, are global in nature and common to economic evaluation of
healthcare in all countries. TheUK “preference” for TTO is nomore than that, for no
scientific case has been made for rejecting Standard Gamble (SG), commonly ac-
knowledged to yield systematically different estimates of utility. Both methods
cannot be correct - one (at least) must be in error. It is patently absurd to consider
them as commensurable equivalents in QALY calculations. In principle, a similar
difficulty arises as new value sets are published, as will be the case in respect of the
5-level version of EQ-5D. Cost-utility analysis reported in the literature reveals a
10-fold difference in incremental benefits (change frombaseline)when EQ-5D/HUI/
SF-6D are used to compute QALYs, sufficient to reverse the location of an ICERwith
respect to any threshold. The central issue is that of updating the choice of a
definitive value set for reference case analysis. This paper argues for a decision-
centric approach inwhich a newmetricmay only be adopted if its use inmeasuring
incremental effectiveness yields results that are consistentwith those based on the
existing reference standard. The argument is exemplified through the analysis of
EQ-5D in published studies.
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VISUAL ASSESSMENT OF FIT OF EQUATIONS TO PREDICT TIME-TO-EVENT
OUTCOMES
Ishak K
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Graphical tests are very useful for assessing the fit of statistical models. In linear
regressionmodels, for instance, a plot of predicted means against observed values
can reveal systematic over- or under-prediction. Similar graphical tests are not
necessarily straightforward for other types of regression models like those based
on parametric survival distributions (e.g., to predict life-expectancy, time to pro-
gression of disease), particularly when multiple predictors are included in the
model. The first complicating issue is censoring, which makes a scatter plot of
individual observed and predicted values difficult to interpret. A better approach is
to plot the empirical distributions (i.e., Kaplan-Meier curves) derived from the ob-
served and predicted values, which inherently accounts for censoring in observed
times. The second andmore intricate issue is the definition of the predicted values.
In linear regression models, predictions represent the mean of the underlying
normal distribution that produced the observation. Since the normal distribution is
symmetric, it is reasonable to expect half of the observations to fall below their
means, and the rest to fall above. Parametric survival distributions are highly
skewed, however, so that the mean would generally be expected to exceed most
observed values. Similar problems arise if one uses the median (or any one partic-
ular percentile) as a reference, or plots the overall predicted curve at the mean
predicted value of the regression parameter (i.e., the scale of the distribution). An
accurate depiction of the overall predicted curve can be obtained instead by gen-
eratingmultiple randomevent times from each individual’s predicted distribution,
and using these to derive the overall predicted curve. The approach will be illus-
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trated with an example that highlights pitfalls involved with more simplistic ap-
proaches.
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CLOSING THE GAP BETWEEN THE FORMULATION AND IMPLEMENTATION OF
CLINICAL PRACTICE GUIDELINES BASED ON EVIDENCE
Gordillo AM, Eslava-Schmalbach J, Amaya Arias AC
Universidad Nacional de Colombia, Bogotá, Colombia
OBJECTIVES: To describe the theoretical approach suggested to close the gap be-
tween recommendations and implementation of clinical practice guidelines
(CPG’s) in Colombia, called harmonization of CPG’s with Public Policy. METHODS:
Perspective paper. A theoretical approach is suggested to harmonize CPG’s recom-
mendationswith public policy. RESULTS: Public policies often don=t get the desired
results, because there is a gap between the decision and the reality. There is a
conceptual and temporal separation between policy formulation and implemen-
tation of decisions, CPG’s are tools to improve quality in the delivery of health
services. However a process od harmonization between recommendations and
implementation with public policy is requested. For this a process of three phases
should be developed: 1) To do a review of existing regulations on health and on the
specific issue of the CPG to harmonize the current policy with recommendations
and identify barriers to the implementation process; 2) To adjust recommenda-
tions of CPG’s to eliminate the barriers encountered with the standards; 3. To state
a negotiation processwith all actors involved in the implementation of the CPG’s at
different levels of care, to generate commitment with them, proposals for changes
in policy and / or administrative, and if it is necessary, to remove barriers
CONCLUSIONS:Harmonization of CPG’s with public policy is a fundamental tool to
improve their implementation. Three phases are proposed. Negotiation could be
the most important one.
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SOCIETAL PERSPECTIVE IN ECONOMIC EVALUATION: CONFUSIONS AND
HIRA’S RECOMMENDATION
Bae S, Lee S, You MY
Health Insurance Review & Assessment Service, Seoul, South Korea
BACKGROUND: Current HIRA’s guideline recommends that economic evaluation
(EE) analysis should take societal perspective, yet the inconsistency in current
guideline has beennoted by the industry side. The purpose of this study is to review
current theoretical trends and discuss the needs of updating HIRA’s current
recommendations.METHODS: To identify the needs of EE guideline revision, HIRA
has reviewed currently updated foreign EE guidelines, and discussed recent theo-
retical trends. In addition, survey results from pharmaceutical companies as well
as decision makers regarding current recommendation were considered. Experts
meetings and working group meetings with industry people were held to share
each party’s perspectives. RESULTS: Pharmaceutical industry suggested that cur-
rent recommendation of taking societal perspective while submitting indirect cost
(especially productivity cost) separately is confusing. Canada (CADTH) has recently
updated its perspective as “publicly funded health care system”, and UK (NICE) has
recommended to take payer(NHS and PSS)’s perspective. Inconsistencies in soci-
etal perspective have also discussed in previous studies and ISPOR consensus
paper. CONCLUSIONS: Given that EE guideline should provide clear minimum
standards for submission parties, a need to clarify current “societal” perspective
has been agreed by relevant parties. “Limited” societal perspective has been pro-
posed to reduce unnecessary confusionswhile reflecting current practice patterns.
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PREVALENCE-BASED VERSUS INCIDENCE-BASED ECONOMIC EVALUATIONS
FOR THE ASSESSMENT OF NEW HEALTH CARE INTERVENTIONS
Mauskopf JA
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OBJECTIVES: To compare the usefulness to decision makers of prevalence-based
versus incidence-based economic evaluations of new health care interventions
METHODS: Comparison of evaluation methods by: population included, time ho-
rizon, outcomes measured, adherence to economic principles, and usefulness to
decision makers. RESULTS: An incidence-based economic evaluation follows a
disease cohort for the duration of the disease and estimates discounted costs and
health gains with alternative interventions. The cost-effectiveness ratio is based
on individual utility maximization and provides information to decision makers
about the efficiency of a new healthcare intervention compared to societal willing-
ness to pay for health gains. It does not estimate annual budget impacts. It gener-
ally does not capture indirect effects on the population. A prevalence-based eco-
nomic evaluation provides estimates of costs and health benefits for the total
population for one year or cumulated over a longer time horizon. The estimated
ratio of cumulative costs and health benefits is not based on economic principles.
Appropriate threshold values for these ratios are those based on a percentage of
Gross Domestic Product as recommended by the World Health Organization. The
prevalence-based cost-effectiveness ratio provides information to decisionmakers
on the affordability of the intervention and the value for money over the selected
time horizon. A prevalence-based analysis can take into account indirect effects of
health care interventions and is, therefore, frequently used for economic evalua-
tions of vaccine programs. CONCLUSIONS: Prevalence-based economic evalua-
tions might be of greater use to health care decision makers than incidence-based
evaluations because, in addition to estimates of value for money, they provide
estimates of affordability and allow comparison of all types of health care inter-
ventions. Threshold values based on economic principles, however, are not appli-
cable for ratios generated using the prevalence-based approach.
DISEASE-SPECIFIC STUDIES
DIABETES/ENDOCRINE DISORDERS – Clinical Outcomes Studies
PDB1
COMPARING HYPOGLYCEMIA RATES FOR TYPE 2 DIABETES PATIENTS
TREATED WITH SAXAGLIPTIN VERSUS SULFONYLUREA: USING CLAIMS DATA
TO REPLICATE A CLINICAL TRIAL
Curkendall SM1, Zhang B2, Lenhart G3, Thomson EE1, Bell KF2, Graham JP2
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OBJECTIVES: A lower rate of hypoglycemia occurred in a Phase 3 trial in T2DM
patients receiving saxagliptin compared to glipizide (sulfonylurea (SU)) added to
metformin. The clinical trial included patient-reported and physician-reported hy-
poglycemia events. The objective of this study was to compare the rates of hypo-
glycemia events that required medical attention in actual clinical practice.
METHODS: MarketScan health care claims data was used to identify patients who
initiated saxagliptin or SU. During the 6 months prior to initiation, patients were
required to have a prescription (Rx) for metformin and no saxagliptin, SU, or other
diabetes Rx. Patients were followed for 4 months to assess the rates of hypoglyce-
mia. During follow-up, patients were required to have at least onemoremetformin
Rx and one additional saxagliptin/SU Rx and no other diabetes Rx. A hypoglycemia
event was defined as a diagnosis of hypoglycemia on an outpatient or emergency
room claim or principal diagnosis on a hospital claim or an outpatient glucagon
injection. SU patients were matched to saxagliptin patients (5 to 1) using propen-
sity scores. The rate ratio was further adjusted for covariates that were not bal-
anced between the matched cohorts using a Poisson regression model. RESULTS:
There were 1,567 saxagliptin, 21,025 SU, and 7,835 propensity-matched SU pa-
tients. The rate of hypoglycemia in the saxagliptin cohort was 1.74 per 100 PY
versus 6.68 in the SU cohort (rate ratio 0.31, 95% CI: 0.14 – 0.60) and 4.45 per 100 PY
in thematched SU sub-group (rate ratio 0.39, 95% CI: 0.17 – 0.77). After multivariate
adjustment, the rate ratio was 0.37 (95% CI: 0.19 – 0.74). CONCLUSIONS: In real
world practice, as was demonstrated in a randomized controlled trial, saxagliptin
patients had a lower risk of hypoglycemia than SU when added to metformin.
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VITAMIN B AND/OR ITS DERIVATIVES FOR DIABETIC KIDNEY DISEASE: A
SYSTEMATIC REVIEW AND META-ANALYSIS
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OBJECTIVES:To assess the benefits andharms of vitamin B and/or its derivatives in
patientswith diabetic kidney disease (DKD).METHODS:Wesearched the Cochrane
Renal Group’s Specialized Register CENTRAL; MEDLINE OVID SP; Hand searching of
renal journals and conference proceedings; EMBASE OVID SP; the International
Clinical Trials Register (ICTRP) Search Portal & ClinicalTrials.gov. Randomized con-
trolled trials (RCTs) comparing vitamin B and/or its derivatives with placebo, no or
active treatment, in patients with DKD were included. RESULTS: Out of 56 identi-
fied studies, four studies were found to be suitable for inclusion. A total of 745
participants were randomized to either vitamin B derivatives (benfotiamine (300
mg TID), thiamine (300 mg OD), vitamin B12 (500 mg OD), folic acid (2.5 mg OD),
vitamin B6 (25 mg OD)) or placebo or active control. Treatment duration ranged
from 3 months to 36 months. We found that none of those derivatives improved
kidney function: improved creatinine clearance (Mean difference (MD) 2.00, 95% CI
-21.78 to 25.78, P 0.87), decreased serum creatinine level (MD 1.00, 95% CI -7.88 to
9.88, P  0.83), reduce level of urinary albumin excretion level (MD: -16.75, 95% CI
-103.44 to 69.94, P 0.70), improved the glomerular filtration rate (MD: -7.00, 95% CI
-22.33 to 8.33, P  0.37) significantly compared to placebo or active control. In
addition,we found that risk ofmyocardial infarction, stroke, revascularization, and
all-cause mortality, in the B-vitamin combination therapy group was increased
(Risk Ratio 1.85, 95%CI 0.99 to 3.45, P 0.05).We also found no significant difference
between vitamin B combination therapy and control group for serious adverse
events, and one or more adverse events. CONCLUSIONS: We did not find any
improvement in kidney function, following use of vitamin B preparation. These
findings require confirmation from high quality randomized trials.
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RISK OF COMPLICATIONS IN TYPE II DIABETIC PATIENTS WITH RENAL
IMPAIRMENT: AN ANALYSIS OF THE RAMQ DATABASE
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OBJECTIVES: Chronic kidney disease is often associated with type II diabetes mel-
litus (T2DM). Patients with T2DM and chronic renal failure are at higher risk of
developing hypoglycemia or metabolic acidosis. The purpose of this study was to
identify treatment patterns in T2DM patients with chronic renal failure and to
estimate the risk of developing complications. METHODS: This study examined
data on patients covered by the Quebec provincial drug reimbursement program
(RAMQ) who had a diagnosis of diabetes, had used a hypoglycemic agent, and had
a diagnosis of chronic renal disease in the period from January 2005 to December
2010. A 1:1 control group of patients with diabetes and without renal disease,
matched for age and gender, was also created. Patients’ characteristics and drug
utilization patterns were analyzed and the risks of experiencing hypoglycemia or
metabolic acidosis were estimated. RESULTS: A total of 4889 patients who had a
diagnosis of diabetes with chronic renal failure were included in this cohort. Aver-
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